BioSpace News Archive

Chromocell Therapeutics Corporation announced the pricing of its initial public offering of 1,100,000 shares of common stock at a public offering price of $6.00 per share.

Arcutis Biotherapeutics, Inc. announced that it will report its fourth quarter and full year financial results and provide a business update on Tuesday, February 27, 2024.

Hepion Pharmaceuticals, Inc. announced that it has entered into a definitive agreement for the immediate exercise of an outstanding Series B common stock purchase warrant held by an institutional investor to purchase an aggregate of 980,393 shares of Hepion common stock for gross proceeds to the Company of approximately $2.0 million.

Viridian Therapeutics, Inc., a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, announced the appointment of Jennifer Tousignant to the role of Chief Legal Officer.

Kinnate Biopharma Inc. announced it has entered into a definitive merger agreement whereby XOMA Corporation will acquire Kinnate for a price per share of Kinnate common stock of between $2.3352 and $2.5879 in cash, consisting of a base cash price of $2.3352 per share and an additional cash amount of up to $0.2527 per share.

Ligand Pharmaceuticals Incorporated announced it has appointed Richard Baxter to the role of Senior Vice President of Investment Operations, and Karen Reeves, M.D., to Senior Vice President of Clinical Strategy and Investments.

Fusion Pharmaceuticals Inc. announced that it has entered into an exclusive worldwide license agreement with Heidelberg University and Euratom represented by the European Commission, Joint Research Centre.

Novartis announced that the US Food and Drug Administration has approved Xolair® for the reduction of allergic reactions, including anaphylaxis, that may occur with accidental exposure to one or more foods in adult and pediatric patients aged 1 year and older with IgE-mediated food allergy.

Sharps Technology, Inc. is working to create new sales and distribution opportunities through the addition of new North American 3PL partnerships to expand its reach into the global healthcare market.

The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.